Skip to search formSkip to main contentSkip to account menu

GEM231

Known as: GEM 231, GEM-231, Gene Expression Modulator 231 
A mixed backbone oligonucleotide exhibiting antitumor activity. GEM-231 is complementary to the RI alpha subunit of Protein Kinase A (PKA), resulting… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Clinical Studies in Patients with Solid Tumors using a Second‐Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I
Abstract: GEM®231 is a second‐generation antisense oligonucleotide targeted against the RIα regulatory subunit of cAMP‐dependent… 
2003
2003
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid…
PURPOSE The purpose of this study was to define the safety and pharmacodynamics of GEM231, a mixed backbone antisense… 
2003
2003
Technology evaluation: GEM-231, Hybridon.
  • P. Yeung
  • Current opinion in molecular therapeutics (Print)
  • 2003
  • Corpus ID: 7375428
GEM-231 (HYBO-165) is an 18mer hybrid oligonucleotide under development by Hybridon for the potential treatment of cancer. Phase… 
2002
2002
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer…
GEM 231, a second-generation antisense oligonucleotide targeted against the RIalpha subunit of protein kinase A (PKA) was co… 
2002
2002
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing…
The RIalpha-subunit of cAMP-dependent protein kinase (PKA) is overexpressed in various human cancers and PKA has been suggested… 
2001
2001
Detection of a mixed-backbone oligonucleotide (GEM 231) in liver and tumor tissues by capillary electrophoresis.
Highly Cited
2000
Highly Cited
2000
A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an… 
2000
2000
Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice.
Biodistribution and metabolism of a mixed backbone oligonucleotide (MBO), GEM 231, targeted to the RIalpha subunit of protein… 
2000
2000
GEM-231 (Hybridon).
  • J. Blay
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 25768629
GEM-231 is an 18-mer hybrid oligonucleotide under development by Hybridon for the potential treatment of cancer. This compound… 
Review
2000
Review
2000
Technology evaluation: GEM-231, Hybridon Inc.
  • J. Blay
  • Current opinion in molecular therapeutics (Print)
  • 2000
  • Corpus ID: 21473171
Hybridon is conducting studies of the DNA methyltransferase gene and has identified specific sequences on mRNA as targets for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)